Tirzepatide Research History: Discovery, Key Trials and Regulatory Timeline

Tirzepatide in one paragraph

Tirzepatide is a prescription medicine that the published literature describes as a single-molecule agonist acting at two incretin receptors: the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor, a class reviewed in detail in 2024 (PMID 39114288). A 2025 review in Nature Reviews Drug Discovery placed it within the broader family of GLP-1-based therapies developed for diabetes, obesity and related indications (PMID 40281304). This page is for educational purposes only and is not medical advice; consult a licensed physician about whether any medicine is appropriate, and about anything relating to prescribing or administration. Background on the molecule itself sits on the tirzepatide overview.

Discovery: where the molecule came from

Tirzepatide did not emerge from a single laboratory discovery event with one named discoverer in the primary literature. It came out of an industry incretin research programme at Eli Lilly and Company that pursued unimolecular co-agonists — peptides engineered so that one sequence engages more than one incretin receptor rather than combining two separate drugs. Reviews of the field describe this dual GIP/GLP-1 design strategy and the pharmacological reasoning behind it (PMID 39114288).

The detailed receptor pharmacology of tirzepatide itself entered the indexed literature in 2020, when researchers reported in JCI Insight that the molecule behaved as an imbalanced and biased dual GIP and GLP-1 receptor agonist — that is, its activity at the two receptors was not symmetrical, and its signalling at the GLP-1 receptor showed bias rather than a simple full-agonist profile (PMID 32730231). That 2020 paper is the usual starting point cited when the question "when was tirzepatide first characterised?" is asked of the peer-reviewed record.

Why the dual-receptor design was studied

Mechanistic reviews published since then set out how GLP-1 receptor activation and GIP receptor activation are thought to contribute to glycaemic and body-weight effects through pancreatic, gastrointestinal and central nervous system pathways; a 2024 review covered mechanisms of action for both GLP-1 and dual GIP/GLP-1 receptor agonists (PMID 39114288), and a 2025 review in Medicina Clínica examined the mechanisms by which GLP-1-based medications are studied in obesity (PMID 40466247).

Chronology of key published studies

The phase 3 diabetes programme (SURPASS), 2021

The SURPASS programme is the cluster of randomised phase 3 trials that brought tirzepatide into mainstream clinical journals. SURPASS-1, published in The Lancet in 2021, was described by its authors as a double-blind, randomised phase 3 trial of the efficacy and safety of the novel dual GIP and GLP-1 receptor agonist in patients with type 2 diabetes (PMID 34186022).

Later the same year, SURPASS-2 was published in The New England Journal of Medicine as a head-to-head randomised comparison of tirzepatide with semaglutide once weekly in patients with type 2 diabetes (PMID 34170647). That design is historically notable because active-comparator trials against another incretin-based medicine were, at the time, less common than placebo-controlled designs.

SURPASS-3, also published in The Lancet in 2021, was a randomised, open-label, parallel-group phase 3 trial that compared once-weekly tirzepatide with once-daily insulin degludec as an add-on to metformin, with or without SGLT2 inhibitors, in patients with type 2 diabetes (PMID 34370970). Taken together, these three 2021 publications established the basic comparator landscape — placebo-controlled, incretin-comparator and insulin-comparator — against which subsequent analyses were framed.

Evidence synthesis: 2022 onward

The first major synthesis arrived quickly. In 2022, a systematic review and meta-analysis in Diabetologia pooled the available randomised evidence on the management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide (PMID 35579691). Reviews of this type are how a research history moves from individual trial results to a class-level picture.

By 2024, tirzepatide was being discussed inside broader class reviews rather than as a stand-alone novelty. A 2024 Diabetes Care review addressed the efficacy and safety of GLP-1 medicines across type 2 diabetes and obesity (PMID 38843460), and a 2025 Nature Reviews Drug Discovery review described GLP-1-based therapies for diabetes, obesity and beyond, including indications under investigation (PMID 40281304).

From glycaemia to body weight

The second arc of the research history concerns body weight. Mechanistic work on how GLP-1-based medications are studied in obesity treatment was reviewed in 2025 (PMID 40466247), and a 2025 review of phase 2 and phase 3 pipelines mapped where GLP-1 receptor agonist development for obesity stood at that point (PMID 40022548).

A distinct question — whether reductions in body weight are maintained — was addressed in SURMOUNT-MAINTAIN, published in The Lancet in 2026 as a multicentre, double-blind, randomised, placebo-controlled trial of tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (PMID 42119587). Maintenance designs are a later stage in a drug's research history than the initial efficacy trials, because they presuppose an established treatment phase.

Longer-horizon comparisons

In 2026, Annals of Internal Medicine published a randomised clinical trial comparing tirzepatide with intensified conventional care after two years of treatment in early type 2 diabetes (PMID 42184419). Two-year randomised comparisons against intensified standard care mark the point at which a medicine's evidence base starts to address durability and real-world treatment strategy rather than short-term endpoints alone.

Regulatory status and timeline

Tirzepatide is a prescription medicine, available only through a licensed prescriber and dispensed under approved product labelling. The sequence that led there follows the publication record above: receptor-level characterisation reported in 2020 (PMID 32730231), randomised phase 3 trials in type 2 diabetes published in 2021 (PMID 34186022, PMID 34170647, PMID 34370970), pooled synthesis in 2022 (PMID 35579691), and subsequent reviews that discuss tirzepatide among the approved GLP-1-based medicines used in type 2 diabetes and obesity (PMID 38843460, PMID 40281304).

Exact approval dates, approved indications, age ranges and labelled warnings are held in national regulatory records — the FDA in the United States, the EMA in the European Union, and equivalent agencies elsewhere — and in the current product labelling, which is updated over time. Those documents, not this page, are the authoritative source for the regulatory status of any particular product in any particular country, and a prescribing clinician is the right person to interpret them for an individual.

Adverse Events in the Tirzepatide Literature: What Studies Report

Safety reporting has been an explicit part of the record from the beginning. SURPASS-1 was published as a trial of efficacy and safety in type 2 diabetes (PMID 34186022), and the 2022 Diabetologia systematic review and meta-analysis pooled randomised data on the management of type 2 diabetes with tirzepatide (PMID 35579691). At class level, a 2024 Diabetes Care review examined efficacy and safety of GLP-1 medicines across type 2 diabetes and obesity (PMID 38843460), and a 2025 Nature Reviews Drug Discovery review surveyed the safety discussion alongside expanding indications for GLP-1-based therapies (PMID 40281304).

This page does not reproduce adverse-event frequencies, because rates are specific to trial populations, comparators and durations, and they belong with the full text of each publication and with the approved labelling. Anyone wanting to know which adverse events are listed, how often they were reported, and what they mean for a particular person should read those sources with a licensed physician.

How to read this research history

• Publication date is not discovery date. The 2020 pharmacology paper described work completed earlier (PMID 32730231).
• Trial titles describe design, not outcome. SURPASS-2 was framed as a comparison with semaglutide once weekly (PMID 34170647); the magnitude of any difference lives in the paper itself.
• Reviews lag primary trials. The 2022 meta-analysis could only pool what had been published by then (PMID 35579691), while pipeline reviews track what is still being tested (PMID 40022548).
• Newer questions are different questions. Weight-maintenance (PMID 42119587) and two-year comparative care designs (PMID 42184419) ask about durability and strategy, not initial response.

Nothing on this page is a recommendation, and no part of it describes how any medicine should be used. Treatment decisions, including whether a prescription medicine is suitable at all, belong to a licensed physician who knows the individual's history.

References

• Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist (JCI Insight, 2020)
• Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (The New England Journal of Medicine, 2021)
• Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial (The Lancet, 2021)
• Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial (The Lancet, 2021)
• Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis (Diabetologia, 2022)
• Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity (Diabetes Care, 2024)
• Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists (Frontiers in Endocrinology, 2024)
• The promise of glucagon-like peptide 1 receptor agonists (GLP-1RA) for the treatment of obesity: a look at phase 2 and 3 pipelines (Expert Opinion on Investigational Drugs, 2025)
• GLP-1-based therapies for diabetes, obesity and beyond (Nature Reviews Drug Discovery, 2025)
• GLP-1-based medications: Mechanisms involved in obesity treatment (Medicina Clínica, 2025)
• Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial (The Lancet, 2026)
• Tirzepatide Versus Intensified Conventional Care After 2 Years of Treatment in Early Type 2 Diabetes: A Randomized Clinical Trial (Annals of Internal Medicine, 2026)